Share This Page

Support & Insight for the Autumn of Life

A Simple Blood Test, SOBA-AD, Detects Alzheimer’s

a-simple-blood-test-soba-ad-detects-1884580608.jpeg

DIAGNOSIS ARTICLE:

The FDA has granted ‘breakthrough device’ designation for a new blood test that can detect Alzheimer’s even before symptoms arise. Learn more.


AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, announced the US Food and Drug Administration (FDA) granted the company Breakthrough Device designation for its SOBA-AD diagnostic in development for Alzheimer’s disease (AD).

The inclusion in the FDA Breakthrough Devices Program means that AltPep can expect prioritized review of the submission of their device.

The long-term potential for the SOBA-AD assay lies in its ability to detect disease early, even before symptoms arise. Early detection may lead to more effective treatments that limit cognitive decline in AD patients.

““Receiving FDA Breakthrough Device designation is an extremely important recognition that will support our efforts to help fill an unmet medical need and bring the SOBA-AD test initially to aid in the diagnosis of AD in patients that present mild cognitive impairment in memory-care and clinical settings,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep.

What is Breakthrough Device designation?

“Existing FDA-cleared diagnostic tests for AD reflect amyloid-beta plaques and neurofibrillary tangles in the brains of patients.

The SOBA-AD test in plasma aims to detect the early molecular triggers of the disease, before plaque formation,” Daggett said.

Breakthrough Device designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Alzheimer’s disease is the most prevalent form of dementia and estimates indicate there are currently 6 million Americans living with AD and this number is projected to grow to 13 million by 2050.

About SOBA-AD

A hallmark of Alzheimer’s disease is the aggregation of the amyloid-beta peptide. AltPep’s proprietary SOBA-AD assay, a simple blood test, detects toxic forms of this peptide at AD’s earlier stages.

Current assessment technologies focus on symptoms or other markers that are only detectable once damage has occurred.

Research has shown that early diagnosis of Alzheimer’s disease may enable access to treatments that could improve cognition and enhance quality of life.

AltPep is also working to develop SOBIN treatments, potential disease-modifying therapies for amyloid diseases, for treatment in concert with early detection.

SOURCE:

Email me when people comment
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter